Li-Cheng Zhou

Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers.

Fms-like tyrosine kinase 3 (FLT3), a member of the type III receptor tyrosine kinase family, is identified as a promising drug target for treatment of acute myeloid leukemia (AML). Here, we designed and synthesized a series of new FLT3 PROTAC degraders by incorporating rigid linkers between gilteritinib and CRBN ligand...